OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
OKYO Pharma Limited has announced the initiation of a Phase 2 clinical trial for OK-101, targeting neuropathic corneal pain (NCP), with the study set to commence in Q3 2024. This follows positive pre-clinical results and a successful Phase 2 trial in dry eye disease (DED) patients, showcasing significant pain relief. With no FDA-approved treatments for NCP currently available, OK-101 could meet a critical unmet medical need in ocular therapy.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.
